Background Direct-acting antiviral (DAA) resistance-associated substitutions (RASs) may jeopardize the potency of DAAs in sufferers with hepatitis C pathogen (HCV). research, the full total prevalence of medically relevant RASs was high, in addition to the treatment group (pre-IFN: 219/403 [54.34%] vs post-IFN: 67/131 [51.15%]). The high prevalence was generally discovered in the NS3 area RAS… Continue reading Background Direct-acting antiviral (DAA) resistance-associated substitutions (RASs) may jeopardize the potency